{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:53:21Z","timestamp":1778298801656,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018534","name":"Medical Innovation Project of Fujian Province","doi-asserted-by":"publisher","award":["2100201"],"award-info":[{"award-number":["2100201"]}],"id":[{"id":"10.13039\/501100018534","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018534","name":"Medical Innovation Project of Fujian Province","doi-asserted-by":"publisher","award":["2019Y9205"],"award-info":[{"award-number":["2019Y9205"]}],"id":[{"id":"10.13039\/501100018534","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-024-03919-2","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T18:29:55Z","timestamp":1733855395000},"page":"314-326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Transarterial Chemoembolization Combined with Lenvatinib Plus Programmed Death-1 Inhibitor for Hepatocellular Carcinoma with the Hepatic Vein and\/or Inferior Vena Cava Tumor Thrombus"],"prefix":"10.1007","volume":"48","author":[{"given":"Long-Wang","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Xia","family":"Nian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-1709","authenticated-orcid":false,"given":"Wei-Zhu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Qing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2923-7267","authenticated-orcid":false,"given":"Ning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"issue":"3","key":"3919_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3919_CR2","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijrobp.2009.07.1730","volume":"78","author":"JE Koo","year":"2010","unstructured":"Koo JE, Kim JH, Lim YS, Park SJ, Won HJ, Sung KB, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys. 2010;78(1):180\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"3919_CR3","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1245\/s10434-012-2646-2","volume":"20","author":"Y Wang","year":"2013","unstructured":"Wang Y, Yuan L, Ge RL, Sun Y, Wei G. Survival benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava\/right atrium tumor thrombus: results of a retrospective cohort study. Ann Surg Oncol. 2013;20(3):914\u201322.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"3919_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jhep.2014.04.032","volume":"61","author":"T Kokudo","year":"2014","unstructured":"Kokudo T, Hasegawa K, Yamamoto S, Shindoh J, Takemura N, Aoki T, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. J Hepatol. 2014;61(3):583\u20138.","journal-title":"J Hepatol"},{"issue":"6","key":"3919_CR5","first-page":"299","volume":"72","author":"FA Eskens","year":"2014","unstructured":"Eskens FA, van Erpecum KJ, de Jong KP, van Delden OM, Klumpen HJ, Verhoef C, et al. Hepatocellular carcinoma: dutch guideline for surveillance, diagnosis and therapy. Neth J Med. 2014;72(6):299\u2013304.","journal-title":"Neth J Med"},{"issue":"10126","key":"3919_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"issue":"10","key":"3919_CR7","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.ejca.2011.12.006","volume":"48","author":"AL Cheng","year":"2012","unstructured":"Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48(10):1452\u201365.","journal-title":"Eur J Cancer"},{"issue":"26","key":"3919_CR8","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1200\/JCO.20.00808","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960\u201370.","journal-title":"J Clin Oncol"},{"key":"3919_CR9","doi-asserted-by":"crossref","unstructured":"Vogel A, Siegler GM, Siebler J, Lindig U, Schulthei\u00df M, M\u00fcller T et al. (2022) IMMUNIB trial (AIO-HEP-0218\/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC). 40(16_suppl):4107\u20134107","DOI":"10.1200\/JCO.2022.40.16_suppl.4107"},{"key":"3919_CR10","doi-asserted-by":"crossref","unstructured":"Kudo M, Ikeda M, Motomura K, Okusaka T, Kato N, Dutcus CE et al. (2020) A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117. 38(4_suppl):513\u2013513","DOI":"10.1200\/JCO.2020.38.4_suppl.513"},{"issue":"9","key":"3919_CR11","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1111\/liv.12818","volume":"35","author":"JW Park","year":"2015","unstructured":"Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155\u201366.","journal-title":"Liver Int"},{"issue":"6","key":"3919_CR12","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1007\/s00330-020-07536-8","volume":"31","author":"HH Chu","year":"2021","unstructured":"Chu HH, Chun SY, Kim JH, Kim PH, Il Gwon D, Ko HK, et al. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. Eur Radiol. 2021;31(6):4232\u201342.","journal-title":"Eur Radiol"},{"issue":"7","key":"3919_CR13","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1007\/s00270-021-02815-3","volume":"44","author":"I Alrashidi","year":"2021","unstructured":"Alrashidi I, Chu HH, Kim JH, Shim JH, Yoon SM, Kim PH, et al. Combined chemoembolization and radiotherapy versus chemoembolization alone for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. Cardiovasc Intervent Radiol. 2021;44(7):1060\u20139.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"3919_CR14","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s00270-008-9342-4","volume":"31","author":"MC Chern","year":"2008","unstructured":"Chern MC, Chuang VP, Cheng T, Lin ZH, Lin YM. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. Cardiovasc Intervent Radiol. 2008;31(4):735\u201344.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"3919_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jvir.2008.09.030","volume":"20","author":"IJ Lee","year":"2009","unstructured":"Lee IJ, Chung JW, Kim HC, Yin YH, So YH, Jeon UB, et al. Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors. J Vasc Interv Radiol. 2009;20(1):22\u20139.","journal-title":"J Vasc Interv Radiol"},{"issue":"4","key":"3919_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3348\/kjr.2007.8.4.311","volume":"8","author":"YJ Kim","year":"2007","unstructured":"Kim YJ, Lee HG, Park JM, Lim YS, Chung MH, Sung MS, et al. Polyvinyl alcohol embolization adjuvant to oily chemoembolization in advanced hepatocellular carcinoma with arterioportal shunts. Korean J Radiol. 2007;8(4):311\u20139.","journal-title":"Korean J Radiol"},{"issue":"1","key":"3919_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380.","journal-title":"Hepatology"},{"issue":"1","key":"3919_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/hepr.13438","volume":"50","author":"M Kudo","year":"2020","unstructured":"Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, et al. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2020;50(1):15\u201346.","journal-title":"Hepatol Res"},{"issue":"2","key":"3919_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/hep.29225","volume":"66","author":"T Kokudo","year":"2017","unstructured":"Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. Hepatology. 2017;66(2):510\u20137.","journal-title":"Hepatology"},{"issue":"6","key":"3919_CR20","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.surg.2017.08.006","volume":"162","author":"S Komatsu","year":"2017","unstructured":"Komatsu S, Kido M, Asari S, Toyama H, Ajiki T, Demizu Y, et al. Particle radiotherapy, a novel external radiation therapy, versus liver resection for hepatocellular carcinoma accompanied with inferior vena cava tumor thrombus: a matched-pair analysis. Surgery. 2017;162(6):1241\u20139.","journal-title":"Surgery"},{"issue":"1","key":"3919_CR21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.radonc.2018.02.030","volume":"129","author":"CH Rim","year":"2018","unstructured":"Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and\/or right atrium: a meta-analysis and systemic review. Radiother Oncol. 2018;129(1):123\u20139.","journal-title":"Radiother Oncol"},{"issue":"1","key":"3919_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40644-015-0043-3","volume":"15","author":"F Duan","year":"2015","unstructured":"Duan F, Yu W, Wang Y, Liu FY, Song P, Wang ZJ, et al. Trans-arterial chemoembolization and external beam radiation therapy for treatment of hepatocellular carcinoma with a tumor thrombus in the inferior vena cava and right atrium. Cancer Imaging. 2015;15(1):7.","journal-title":"Cancer Imaging"},{"key":"3919_CR23","doi-asserted-by":"crossref","unstructured":"Ning S, Li X, Ma X, Liu J, Chang X (2023) Efficacy of TACE Combined with Lenvatinib Plus Sintilimab for Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava and\/or Right Atrium. J Hepatocell Carcinoma. 101511\u20131525","DOI":"10.2147\/JHC.S410967"},{"issue":"5","key":"3919_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","volume":"18","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293\u2013313.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"3919_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1148\/radiol.211028","volume":"303","author":"DJ Tischfield","year":"2022","unstructured":"Tischfield DJ, Gurevich A, Johnson O, Gatmaytan I, Nadolski GJ, Soulen MC, et al. Transarterial embolization modulates the immune response within target and nontarget hepatocellular carcinomas in a rat model. Radiology. 2022;303(1):215\u201325.","journal-title":"Radiology"},{"issue":"3","key":"3919_CR26","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12072-021-10184-9","volume":"15","author":"Z Fu","year":"2021","unstructured":"Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, et al. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatol Int. 2021;15(3):663\u201375.","journal-title":"Hepatol Int"},{"issue":"6","key":"3919_CR27","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/cam4.1517","volume":"7","author":"M Matsuki","year":"2018","unstructured":"Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7(6):2641\u201353.","journal-title":"Cancer Med"},{"key":"3919_CR28","doi-asserted-by":"crossref","unstructured":"Chan SL, Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z et al. (2024) Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with\/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma. 42:4122\u20134122","DOI":"10.1200\/JCO.2024.42.16_suppl.4122"},{"key":"3919_CR29","first-page":"141109771","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Wu J, Wu J, Fu Y, Zeng Z, Li Y, et al. Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study. Front Immunol. 2023;14:141109771.","journal-title":"Front Immunol"},{"issue":"1","key":"3919_CR30","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1186\/s12913-022-08661-4","volume":"22","author":"T Zhou","year":"2022","unstructured":"Zhou T, Wang X, Cao Y, Yang L, Wang Z, Ma A, et al. Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma. BMC Health Serv Res. 2022;22(1):1367.","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"3919_CR31","doi-asserted-by":"publisher","first-page":"7305","DOI":"10.3390\/curroncol29100575","volume":"29","author":"L Zhang","year":"2022","unstructured":"Zhang L, Sun J, Wang K, Zhao H, Zhang X, Ren Z. First- and second-line treatments for patients with advanced hepatocellular carcinoma in China: a systematic review. Curr Oncol. 2022;29(10):7305\u201326.","journal-title":"Curr Oncol"},{"issue":"1","key":"3919_CR32","doi-asserted-by":"publisher","first-page":"102060","DOI":"10.1016\/j.clinre.2022.102060","volume":"47","author":"M Wang","year":"2022","unstructured":"Wang M, Sun L, Han X, Ren J, Li H, Wang W, et al. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy. Clin Res Hepatol Gastroenterol. 2022;47(1):102060.","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03919-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-024-03919-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-024-03919-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T14:54:03Z","timestamp":1741359243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-024-03919-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3919"],"URL":"https:\/\/doi.org\/10.1007\/s00270-024-03919-2","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All of the authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study followed the guidelines set forth in the Declaration of Helsinki and received approval from the Ethics Committee at Fujian Medical University Union Hospital in Fuzhou, China. A waiver of informed consent was granted by Fujian Medical University Union Hospital due to the anonymous and retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable. No information or images in this manuscript can lead to the identification of study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}